NCT05241028View on ClinicalTrials.gov

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2029

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Ensartinib

Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity

Trial Locations (1)

050011

RECRUITING

Jun Feng Liu, Shijiazhuang

All Listed Sponsors
lead

Hebei Medical University Fourth Hospital

OTHER